AR060903A1 - Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp - Google Patents
Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetpInfo
- Publication number
- AR060903A1 AR060903A1 ARP070102054A ARP070102054A AR060903A1 AR 060903 A1 AR060903 A1 AR 060903A1 AR P070102054 A ARP070102054 A AR P070102054A AR P070102054 A ARP070102054 A AR P070102054A AR 060903 A1 AR060903 A1 AR 060903A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- halogenated
- alkoxy
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a compuestos de formula (1) descriptos en la presente utiles como inhibidores de CETP, composiciones que los contienen y métodos para utilizarlos. Reivindicacion 1: Un compuesto de formula (1) donde: L es un enlace covalente u O; Q es arilo C6-10 o heteroarilo de 5 o 6 miembros; n es 0 a 3, m es 0 a 3; R1 es alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, heteroarilo de 5 o 6 miembros, donde cada uno de alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, y heteroarilo de 5 o 6 miembros puede estar opcionalmente sustituido; o R1 es fenilo opcionalmente sustituido con 1 o 2 miembros seleccionados de Ra y Rb, donde Ra y Rb se seleccionan independientemente del grupo integrado por alquilo C1-4 opcionalmente sustituido, alquilo C1-4 halogenado, alquenilo C2-4 opcionalmente sustituido, alquinilo C2-4 opcionalmente sustituido, alcoxi C1-4 opcionalmente sustituido, alcoxi C1-4 halogenado, alquiltio C1-4 opcionalmente sustituido, halo, ciano e hidroxi, o Ra y Rb junto con los átomos de carbono del anillo fenilo a los cuales están unidos forman un heterociclilo de 5 o 6 miembros opcionalmente sustituido fusionado al anillo fenilo; cada R2 se selecciona independientemente de halo, hidroxi, ciano, alcoxi C1-4, alcoxi C1-4 halogenado, alquilo C1-4, alquilo C1-4 halogenado, alquenilo C2-4, alquinilo C2-4 y -C(O)H; cada R3 se selecciona independientemente de alquilo C1-4, alquilo C1-4 halogenado, alquenilo C2-4, alquinilo C2-4, alcoxi C1-4, halo, ciano e hidroxi; R4 es alquilo C1-10 opcionalmente sustituido con 1-3 miembros seleccionados en forma independiente de halo, oxo, hidroxi, alquilo C1-4 halogenado, alcoxi C1-4, cicloalquilo C3-8, CN, ter- butildimetilsililoxi, heterociclilo y -NRcRd, donde Rc y Rd se seleccionan en forma independiente de H, alquilo C1-3 opcionalmente sustituido, -C(O)alquilo C1-3, -C(O)O-alquilo C1-3, y -SO2alquilo C1-3, o R4 es alquilo C1-6 sustituido con heteroarilo o fenilo sustituido con 1 a 3 miembros seleccionados en forma independiente de halo, hidroxi, alquilo C1-3, alquilo C1-3 halogenado, alcoxi C1-4, y alcoxi C1-4 halogenado, o sus enantiomeros, diastereomeros, tautomeros, solvatos o sales aceptables para uso farmacéutico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79946806P | 2006-05-11 | 2006-05-11 | |
| US87115306P | 2006-12-21 | 2006-12-21 | |
| US11/746,755 US7928238B2 (en) | 2006-05-11 | 2007-05-10 | 1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060903A1 true AR060903A1 (es) | 2008-07-23 |
Family
ID=39562869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102054A AR060903A1 (es) | 2006-05-11 | 2007-05-11 | Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7928238B2 (es) |
| EP (1) | EP2034998A1 (es) |
| JP (1) | JP2009536953A (es) |
| AR (1) | AR060903A1 (es) |
| CA (1) | CA2651942A1 (es) |
| PE (1) | PE20080254A1 (es) |
| TW (1) | TW200811109A (es) |
| WO (1) | WO2008079427A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2013080999A1 (ja) | 2011-11-29 | 2013-06-06 | 興和株式会社 | ＮＰＣ１Ｌ１及び／又はＬＩＰＧ ｍＲＮＡの発現抑制剤並びに肥満症の予防及び／又は治療剤 |
| WO2014118099A1 (en) | 2013-01-30 | 2014-08-07 | Basf Se | Fungicidal naphthoquinones and derivatives |
| US9688630B2 (en) | 2013-10-10 | 2017-06-27 | Merck Sharp & Dohme Corp. | 3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein |
| WO2015074064A2 (en) | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
| EP3071205B1 (en) | 2013-11-18 | 2020-02-05 | Forma Therapeutics, Inc. | Benzopiperazine compositions as bet bromodomain inhibitors |
| CN105541690B (zh) * | 2015-12-16 | 2018-08-21 | 江苏恒盛药业有限公司 | 一种氮杂环丁酮衍生物的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61227506A (ja) | 1985-04-01 | 1986-10-09 | Nippon Tokushu Noyaku Seizo Kk | カルバモイルイミダゾ−ル類、その中間体、それらの製法並びに除草剤又は農園芸用殺菌剤 |
| ATE182591T1 (de) | 1991-09-12 | 1999-08-15 | Smithkline Beecham Plc | 5-ht4 rezeptor antagonisten |
| US5616537A (en) | 1992-07-03 | 1997-04-01 | Kumiai Chemical Industry Co., Ltd. | Condensed heterocyclic derivatives and herbicides |
| CN1160399A (zh) | 1994-10-13 | 1997-09-24 | 美国辉瑞有限公司 | 苯并吡喃和苯并稠合化合物、其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途 |
| AU1106195A (en) | 1994-11-09 | 1996-06-06 | Novo Nordisk A/S | Heterocyclic compounds, their preparation and use |
| EP0801060A1 (en) | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
| DE19638484A1 (de) | 1996-09-20 | 1998-03-26 | Basf Ag | Hetaroylderivate |
| DE19638486A1 (de) | 1996-09-20 | 1998-03-26 | Basf Ag | Hetaroylderivate |
| US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
| US6642228B1 (en) | 1999-06-24 | 2003-11-04 | Toray Industries, Inc. | α1b-adrenergic receptor antagonists |
| GB9919411D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| US6451830B1 (en) | 1999-09-23 | 2002-09-17 | G.D. Searle & Co. | Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity |
| WO2001057003A1 (en) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa |
| US7125891B2 (en) | 2000-10-30 | 2006-10-24 | Janssen Pharmaceutica N.V. | Tripeptidyl peptidase inhibitors |
| AU2002248221B2 (en) | 2000-10-31 | 2006-08-17 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| ITMI20012060A1 (it) | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | Nuovi eterocilcli n-acilati |
| CN1589258A (zh) | 2001-10-16 | 2005-03-02 | 雷迪实验室有限公司 | 新的β－苯基－α－氧取代的丙酸衍生物,它的制备方法和它们制备药学上重要的化合物的应用 |
| US7015219B2 (en) | 2001-12-19 | 2006-03-21 | Bristol-Myers Squibb Company | 3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators |
| US7071210B2 (en) | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| WO2004072041A1 (en) | 2003-02-12 | 2004-08-26 | Care X S.A. | Tetrahydroquinolines as agonists of liver- x receptors |
| WO2004072042A2 (en) | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivative and their use for modulation of lxr activity |
-
2007
- 2007-05-10 JP JP2009510167A patent/JP2009536953A/ja not_active Withdrawn
- 2007-05-10 WO PCT/US2007/068628 patent/WO2008079427A1/en active Application Filing
- 2007-05-10 CA CA002651942A patent/CA2651942A1/en not_active Abandoned
- 2007-05-10 US US11/746,755 patent/US7928238B2/en not_active Expired - Fee Related
- 2007-05-10 EP EP07872214A patent/EP2034998A1/en not_active Withdrawn
- 2007-05-11 AR ARP070102054A patent/AR060903A1/es unknown
- 2007-05-11 TW TW096116729A patent/TW200811109A/zh unknown
- 2007-05-11 PE PE2007000573A patent/PE20080254A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20070265304A1 (en) | 2007-11-15 |
| WO2008079427A1 (en) | 2008-07-03 |
| CA2651942A1 (en) | 2008-07-03 |
| EP2034998A1 (en) | 2009-03-18 |
| PE20080254A1 (es) | 2008-04-11 |
| US7928238B2 (en) | 2011-04-19 |
| JP2009536953A (ja) | 2009-10-22 |
| TW200811109A (en) | 2008-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060903A1 (es) | Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp | |
| AR067413A1 (es) | Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer | |
| AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
| AR060904A1 (es) | Derivados de 3,4-dihidro-2h-benzo [1,4] oxazina y tiazina como inhibidores de cetp | |
| ES2686501T3 (es) | Pirazolo[1,5-a]piridinas sustituidas como inhibidores de la quinasa del receptor de tropomiosina (Trk) | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| ECSP067013A (es) | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 | |
| AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
| CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| ES2393824T3 (es) | Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucoquinasa para el tratamiento de diabetes mellitus | |
| AR085304A1 (es) | Imidazo[5,1-f][1,2,4]triazinas para el tratamiento de trastornos neurologicos | |
| AR073406A1 (es) | Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer. | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| AR084412A1 (es) | Compuestos de piridina fusionados, utiles como inhibidores de caseina quinasa, y las composiciones farmaceuticas que los contienen | |
| AR078228A1 (es) | Inhibidores de cyp17 | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| CO6190512A2 (es) | Compuestos antagonistas del receptor de glucagon composiciones que contienen dichos compuestos y procedimientos de uso | |
| AR063912A1 (es) | Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas. | |
| AR073136A1 (es) | Compuestos de pirrol | |
| CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |